Searched for
BIOTECHNOLOGY MAJOR BIOCON
“Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- 'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- USFDA issues CRL for proposed biosimilar Insulin-R: BioconThe CRL cites additional data required in the BLA submission and an expectation of satisfactory implementation of a corrective and preventi...
- Biocon gets USFDA nod for generic productBiocon Pharma, a subsidiary of the company, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new ...
- USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...
- Biocon to acquire 26% stake in Hinduja Renewables TwoThe cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 percent stake on a fully diluted basis in one or more tranches, it ...
- Biocon rises 5% after launch of Ogivri in US marketBiotechnology major Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast...
- Biocon Q1 net up 17% at Rs 147 croreTotal revenue of the company rose to Rs 952 crore for the first quarter, as compared to Rs 857 crore during the same period of correspondin...
- Biocon to further develop insulin TregopilBiocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...
- Biocon shares gain over 5%, hit 52-week high intra-dayShares of biotechnology major Biocon today surged over 5 per cent after the company launched advanced novel therapy for the treatment of He...
- Biocon completes 10 per cent stake sale in SyngeneBiotechnology major Biocon today concluded sale of 10 per cent stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company Pr...
- Biocon No 6 among top 20 global Biotech employersBiotechnology major Biocon today said it has been ranked No 6 on the annual global 'Top Twenty Employers' list for the Bio-Pharma sector by...
- Biocon eyes $1 bn revenue in next three fiscals: Kiran Mazumdar ShawBiotechnology major Biocon on Tuesday said it aims to achieve revenues of USD 1 billion in the next three years.
- Biocon Q2 net moves up 20% to Rs 89.22 croreBiocon reported 20.26% increase in net profit for the quarter ended September 30 to Rs 89.22 crore on the back of strong sales.
- Citigroup assigns 'sell' on BioconForeign brokerage Citigroup has assigned a ‘sell’ rating on integrated biotechnology company Biocon citing higher vulnerability of the comp...
Load More
